Location of the ER mutations and frequencies per cohort.

Slides:



Advertisements
Similar presentations
The origin of metastatic disease: clues from genomics 7/13/2011.
Advertisements

سرطان الثدي Breast Cancer
Breast cancer. Breast cancer. A, antitumor activity of abemaciclib in a human xenograft model (T47D) of ER-positive, HER2-negative breast cancer. Athymic.
WES detects a limited number of clinically targetable alterations in patients with advanced cancer. WES detects a limited number of clinically targetable.
Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.
High-throughput analysis of informative CpG sites for the four studied tumor suppressor genes (A-D). High-throughput analysis of informative CpG sites.
Clinical applications of CTCs and ctDNA as liquid biopsy for personalized medicine. Clinical applications of CTCs and ctDNA as liquid biopsy for personalized.
Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.
Genetic landscape of salivary duct carcinoma.
Presentation and progression of glioblastoma with PNET features in an adult patient. Presentation and progression of glioblastoma with PNET features in.
Cancer mutations in enriched RBP motifs.
Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.
Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.
Frequent alterations identified and potential actionability.
Inhibitory effect of different doses of IP6 on prostate tumor progression in TRAMP mice. Inhibitory effect of different doses of IP6 on prostate tumor.
KIT mutations in GISTs. A, amino acid sequence of KIT exon 11 mutations in clinical GIST biopsies. –, amino acids that are deleted; italicized amino acids,
Development of 28 public molecular laboratories in France for molecular testing. Development of 28 public molecular laboratories in France for molecular.
Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.
Vascular staining in CWR22R xenograft tumors.
Reported frequencies stratified according to preoperative chemotherapy
Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.
FGFR3 mutation analysis of a selection of urine samples from patients included with an FGFR3-mutant (MT) tumor. FGFR3 mutation analysis of a selection.
MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting Sox2. MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting.
Personalized, 16-plex assays accurately detect ctDNA ahead of clinical relapse. Personalized, 16-plex assays accurately detect ctDNA ahead of clinical.
Antitumor activity of AMG 102 in combination with bevacizumab or motesanib. Antitumor activity of AMG 102 in combination with bevacizumab or motesanib.
EN1 expression in breast cancer and clinical outcome.
Somatic mutational rates and survival analysis of IBD-CRC.
A, unsupervised clustering of all BRCA1 (red), BRCA2 (blue), and sporadic (green) breast tumors of our collection using the regions reported as discriminative.
Location of common clinically relevant mutations in EGFR
Duration of treatment and intervals of radiographic and ctDNA response
Survival risk prediction analysis and application of the metastasis gene signature. Survival risk prediction analysis and application of the metastasis.
Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.
Nested RT-PCR of Mammaglobin and CK19 mRNA in plasma and circulating cells of controls (C) and patients (T) with breast cancer. Nested RT-PCR of Mammaglobin.
Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer (patient 6). Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer.
HGSOC mutational processes are established early and are patient-specific. HGSOC mutational processes are established early and are patient-specific. A,
Example inverse FF-OCT images (left column) and corresponding histology images (right column) of ovarian metastases. Example inverse FF-OCT images (left.
Representative photograph of somatic mutations detected by PCR-SSCP.
Antitumor activity. Antitumor activity. A, maximum change in target lesion size from baseline assessed according to RECIST 1.0 (n = 26). Six patients had.
Correlations of the breast cancer hypoxia metagene with Ki67 and the proliferation metagene. Correlations of the breast cancer hypoxia metagene with Ki67.
Clustering analysis of DTC-associated genes.
MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.
Representative images demonstrating LOH in breast cancer patients’ paired BM aspirate and primary tumors (T) at D14S62, D14S51, and D8S321, respectively.
A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.
Molecular heterogeneity can drive mixed response and treatment failure in EGC. A, PET images from Patient #4 obtained before treatment and upon disease.
Prevalence of germline T790M.
Frequent coamplification of RTKs in MET-amplified EGC
Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.
Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Expression.
Representative patient responses to ulixertinib.
Transcriptional activity and growth of mutant ER in a breast cancer cell line. Transcriptional activity and growth of mutant ER in a breast cancer cell.
Mean percentage change from baseline in total IGF-I and the R1507 serum concentration values following a single i.v. administration of R mg/kg (n.
A, Selected 4 quantitative imaging features significantly associated with 3 imaging subtypes, including tumor volume, tumor sphericity, tumor homogeneity.
Specific reaction with MIB1, M30, and CD31 monoclonal antibodies in primary human cervical carcinoma before (A, C, and E) and after (B, D, and F) Tam treatment.
Global mutational landscape of the 170 lung adenocarcinoma patients (discovery cohort). Global mutational landscape of the 170 lung adenocarcinoma patients.
Molecular definitions of lung adenocarcinoma subtypes.
Genomic determinants of response to cytotoxic chemotherapy.
The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.
Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations.
Genetic analysis suggests the presence of four clinically relevant groups of histologically defined anaplastic oligodendrogliomas. Genetic analysis suggests.
Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. A,
A, heatmap of copy number alterations determined by array CGH for a panel of 79 frozen NSCLC samples. A, heatmap of copy number alterations determined.
PIK3CA somatic mutation and amplification frequency in prostate cancer
Mechanism by which flavopiridol induces cell cycle arrest and apoptosis in rhabdoid tumor cells. Mechanism by which flavopiridol induces cell cycle arrest.
Venn diagram showing the overlap of PD-L1 overexpression, MSI-NGS–high, and TML-high in all gastrointestinal tumors, with all three markers tested (N =
Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.
High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies. High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies.
Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.
Driver pathways and key genes in OSCC
CONSORT diagram. a, 5 had a major treatment violation (3 refused and 2 received wrong treatment) but were included in the analyses; b, 4 had a major treatment.
Waterfall plots in 82 ipilimumab-refractory patients receiving nivolumab (3 mg/kg) with (n = 14) or without (n = 82) a peptide vaccine. Waterfall plots.
Presentation transcript:

Location of the ER mutations and frequencies per cohort. Location of the ER mutations and frequencies per cohort. A, diagram of ER with detected predicted somatic point mutations designated with a circle at the representative protein position. *, a mutation found in a primary ER− breast cancer. B, frequency of the 538/537 substitution mutations and ER amplifications per cohort in ER+ tumors showing an increase in frequency with the progression and increase in number of treatment lines for ER+ breast cancer. Each bar represents the percentage of patients with a mutation and the different colors within the bars represent the frequency of the indicated alteration. In the EM+ cohort one patient had both an ER amplification and a Y537S mutation. AF1, activation function 1; AF2, activation function 2; EM+, early metastatic ER+ disease; LM+, late metastatic ER+ breast cancer. Rinath Jeselsohn et al. Clin Cancer Res 2014;20:1757-1767 ©2014 by American Association for Cancer Research